All Outputs (78)

Testing for hepatitis C virus infection in UK prisons: what actually happens? (2019)
Journal Article

Prisons are a key demographic in the drive to eradicate hepatitis C virus (HCV) as a major public health threat. We have assessed the impact of the recently introduced national opt-out policy on the current status of HCV testing in 14 prisons in the... Read More about Testing for hepatitis C virus infection in UK prisons: what actually happens?.

The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England (2019)
Journal Article

Background and Aims: Previous studies have shown low rates of diagnosis and treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID). Our aims were to test the effect of a complex intervention (“HepCATT”) in drug and alcohol c... Read More about The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England.

SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis (2018)
Journal Article

Extracellular matrix (ECM) deposition and resultant scar play a major role in the pathogenesis and progression of liver fibrosis. Identifying core regulators of ECM deposition may lead to urgently needed diagnostic and therapetic strategies for the d... Read More about SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis.

Short-term changes observed in multi-parametric liver MRI following therapy with direct acting antivirals in chronic hepatitis C virus patients (2018)
Journal Article

Methods: We applied multiparametric MRI to assess changes in liver composition, perfusion and blood flow in 17 patients before DAA therapy and after treatment completion (within 12 weeks of last DAA tablet swallowed). Results: We observed changes in... Read More about Short-term changes observed in multi-parametric liver MRI following therapy with direct acting antivirals in chronic hepatitis C virus patients.

Epidemiology and natural history of hepatitis C virus infection among children and young people (2018)
Journal Article

Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? (2018)
Journal Article

Virus infections cause diseases of different severity ranged from mild infection e.g. common cold into life threatening diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus infections represent 44% of newly emerging infections. Althou... Read More about Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?.

Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles (2018)
Journal Article

Nucleoside analogues are active therapeutic agents for different types of diseases e.g. Cancer and virus infections. However, they are associated with several side effects due to off-target accumulation. Particulate delivery systems such as nanoparti... Read More about Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles.

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus (2018)
Journal Article

Objective: Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income... Read More about Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.

Pretreatment lesions on magnetic resonance imaging in patients with hepatitis C virus infection diagnosed with hepatocellular carcinoma after initiating direct-acting antiviral therapy (2018)
Journal Article

Understanding hepatitis C intervention success: qualitative findings from the HepCATT study (2018)
Journal Article

The United Kingdom has committed to eliminating viral hepatitis as a public health threat. Innovative interventions for marginalized populations are required to realize this goal. In 2016, the HepCATT study team implemented a complex hepatitis C (HCV... Read More about Understanding hepatitis C intervention success: qualitative findings from the HepCATT study.

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease (2018)
Journal Article

Aims. Needle biopsy remains essential for diagnosis in assessment of liver disease, although there remains associated risk. Examination is largely limited to subjective evaluation and biopsies are not exploited to provide personalised prognostic info... Read More about Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.

Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review (2018)
Journal Article

Hepatitis C virus (HCV)-infected patients are at risk of developing hepatocellular carcinoma (HCC). Individuals at heightened riskcould be targeted by intensive follow-up surveillance. We have conducted a systematic review of the literature to identi... Read More about Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review.

Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals (2017)
Journal Article

Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case-finding, referral, treatment uptake and retention i... Read More about Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.

SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis (2017)
Journal Article

Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptio... Read More about SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis.

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis (2017)
Journal Article

Varicella zoster virus (VZV) infection has been implicated in multiple sclerosis (MS), but direct causal involvement has been disputed. Nevertheless, knowledge of VZV exposure is important, given the risk of serious complications of first exposure wh... Read More about Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.

Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK (2017)
Journal Article

© 2017 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc. Designing services with the capacity and expertise to meet the needs of the chronic hepatitis C (CHC) population in the era of direct acting antivirals (DAAs), and w... Read More about Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.

Cohort profile: the Hepatitis C Virus (HCV) Research UK clinical database and biobank (2017)
Journal Article

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016)
Journal Article

© 2016 The Author(s). Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as being associated with the development of alco... Read More about MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article

Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, h... Read More about Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article

© 2016 European Association for the Study of the Liver. Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcom... Read More about Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.